## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($312.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Panagora Asset Management Inc. Cuts Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251204T000812 | Neutral | Relevance: 99%
-  Panagora Asset Management Inc. reduced its stake in Elevance Health (NYSE:ELV) by 8.9% in Q2, selling 4,240 shares and retaining 43,219 shares valued at $16.81 million. Despite this reduction, Elevance Health exceeded Q3 earnings and revenue estimates, reporting EPS of $6.03 and $50.09 billion in revenue, up 12% year-over-year. Analysts currently hold a consensus "Hold" rating with a target price of $398.44, and the company has declared a quarterly dividend of $1.71.

**2. Beutel Goodman & Co Ltd. Acquires Shares of 753,653 Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251205T084232 | Bullish | Relevance: 99%
-  Beutel Goodman & Co Ltd. has acquired a significant new position in Elevance Health, Inc. (NYSE:ELV), purchasing 753,653 shares valued at approximately $293.14 million during the second quarter. This acquisition represents about 0.33% of the health benefits company. Elevance Health, which recently reported strong Q3 earnings beating analyst estimates, also declared a quarterly dividend of $1.71 per share.

**3. What Makes Elevance Health (ELV) an Investment Choice?**
- Source: Insider Monkey | 20251204T143111 | Somewhat-Bullish | Relevance: 99%
- Harding Loevner's "Global Equity Strategy" investor letter for Q3 2025 highlighted Elevance Health, Inc. (NYSE: ELV) as a new US holding. The firm values Elevance Health for its entrenched position in regulated markets and more palatable valuation compared to competitors. Despite its potential, the firm suggests that some AI stocks may offer higher returns in a shorter timeframe.

**4. Elevance Health Expands Virtual Assistant to Help Members Navigate Healthcare with Confidence**
- Source: Business Wire | 20251205T190218 | Bullish | Relevance: 99%
-  Elevance Health has expanded its Virtual Assistant, available through the Sydney Health app and affiliated health plan websites, to help approximately 22 million commercial health plan members navigate their healthcare. This digital tool uses conversational technology to provide personalized guidance on coverage, benefits, and care, aiming to simplify the healthcare journey. The Virtual Assistant assists members in tasks such as checking claims, paying bills, finding in-network providers, and understanding costs, with planned expansion to Medicare members in 2026.

**5. Invesco Ltd. Has $821.94 Million Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251204T120812 | Bullish | Relevance: 99%
-  Invesco Ltd. slightly reduced its stake in Elevance Health, Inc. by 0.1% in the second quarter, maintaining a substantial position valued at approximately $821.94 million. Institutional investors collectively own 89.24% of Elevance Health, with several other hedge funds also adjusting their holdings. Analysts generally show positive sentiment towards ELV, giving it a "Moderate Buy" rating with a consensus price target of $398.44.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.3B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.1 |
| Current P/E | 11.0 |
| YoY Growth | -9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.9% (minimal 5-day change). Below STRENGTH zone by 4.8pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.06), confirming momentum. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.85% (CS: 34) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | 1.06 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $330.75
- **Stop Loss:** $312.85 (5.4% risk)
- **Target:** $348.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $8,930.25
- **Portfolio %:** 8.93%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*